Macular Edema – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Macular Edema – Pipeline Review, H2 2017’, provides an overview of the Macular Edema pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Macular Edema

The report reviews pipeline therapeutics for Macular Edema by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Macular Edema therapeutics and enlists all their major and minor projects

The report assesses Macular Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Macular Edema

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Macular Edema

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Macular Edema pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ActiveSite Pharmaceuticals Inc

Coherus BioSciences Inc

Lupin Ltd

Mabion SA

OMEICOS Therapeutics GmbH

Promedior Inc

Taiwan Liposome Company Ltd

Xbrane Biopharma AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Macular Edema - Overview 6

Macular Edema - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Products under Development by Companies 10

Macular Edema - Therapeutics Assessment 11

Assessment by Target 11

Assessment by Mechanism of Action 13

Assessment by Route of Administration 15

Assessment by Molecule Type 17

Macular Edema - Companies Involved in Therapeutics Development 19

ActiveSite Pharmaceuticals Inc 19

Coherus BioSciences Inc 19

Lupin Ltd 20

Mabion SA 20

OMEICOS Therapeutics GmbH 21

Promedior Inc 21

Taiwan Liposome Company Ltd 21

Xbrane Biopharma AB 22

Macular Edema - Drug Profiles 23

ACX-107 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

aflibercept biosimilar - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

ASPPDC-020 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

dexamethasone sodium phosphate - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

HO-10 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

OMT-28 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

PRM-167 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

ranibizumab biosimilar - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

ranibizumab biosimilar - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

ranibizumab biosimilar - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Macular Edema - Dormant Projects 36

Macular Edema - Discontinued Products 37

Macular Edema - Product Development Milestones 38

Featured News & Press Releases 38

Jul 25, 2017: TLC to Receive Government Grant for Development of Ophthalmology Product Candidate TLC399 38

Oct 01, 2015: Patent Granted by SIPO for TLCs Ophthalmic Drug Delivery System 38

Jan 06, 2015: Government Subsidy of NT$17.6M granted for TLC’s Ophthalmology Drug Phase I/II trial 39

Dec 23, 2013: TLC receives FDA IND approval for Sustained Release Macular Disease Drug 39

Sep 24, 2013: Patent Approval granted by USPTO for TLC’s BioSeizer Platform 39

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Tables

List of Tables

Number of Products under Development for Macular Edema, H2 2017 7

Number of Products under Development by Companies, H2 2017 9

Products under Development by Companies, H2 2017 10

Number of Products by Stage and Target, H2 2017 12

Number of Products by Stage and Mechanism of Action, H2 2017 14

Number of Products by Stage and Route of Administration, H2 2017 16

Number of Products by Stage and Molecule Type, H2 2017 18

Macular Edema – Pipeline by ActiveSite Pharmaceuticals Inc, H2 2017 19

Macular Edema – Pipeline by Coherus BioSciences Inc, H2 2017 19

Macular Edema – Pipeline by Lupin Ltd, H2 2017 20

Macular Edema – Pipeline by Mabion SA, H2 2017 20

Macular Edema – Pipeline by OMEICOS Therapeutics GmbH, H2 2017 21

Macular Edema – Pipeline by Promedior Inc, H2 2017 21

Macular Edema – Pipeline by Taiwan Liposome Company Ltd, H2 2017 22

Macular Edema – Pipeline by Xbrane Biopharma AB, H2 2017 22

Macular Edema – Dormant Projects, H2 2017 36

Macular Edema – Discontinued Products, H2 2017 37

List of Figures

List of Figures

Number of Products under Development for Macular Edema, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products by Targets, H2 2017 11

Number of Products by Stage and Targets, H2 2017 11

Number of Products by Mechanism of Actions, H2 2017 13

Number of Products by Stage and Mechanism of Actions, H2 2017 13

Number of Products by Routes of Administration, H2 2017 15

Number of Products by Stage and Routes of Administration, H2 2017 15

Number of Products by Molecule Types, H2 2017 17

Number of Products by Stage and Molecule Types, H2 2017 17

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports